Teva gets FDA breakthrough status for SD-809 to treat tardive dyskinesia

Israel-based Teva Pharmaceutical Industries has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for SD-809 (deutetrabenazine) to treat patients with moderate to severe tardive dyskinesia, a hyperkinetic moveme…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news